Atyr Pharma Inc. (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
$0.75
-$0.23(-5.91%)
At close: 4:00 PM EST
$0.75
-$0.23(-5.91%)
Day’s Range― - ―
52-Week Range$0.64 - $7.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)1.25M
Market Cap
$73.73M
Enterprise Value$75.02M
Total Cash (Recent Filing)$78.69M
Total Debt (Recent Filing)$12.03M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding98,051,210
10 Day Avg. Volume955,323
30 Day Avg. Volume1,254,707
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue394.87
Enterprise Value/Gross Profit-3.36
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$7.33Price Target Upside877.33% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$3.85M
Bulls Say, Bears Say
Bulls Say
Alternative IndicationPositive interim Phase 2 data in scleroderma‑related lung disease create an alternative development pathway for efzofitimod and could support a focused approval strategy in that indication.
Durable Clinical BenefitsEfzofitimod demonstrated potential to durably improve multiple disease‑related health outcomes despite missing the study's primary endpoint, indicating meaningful clinical activity that could support future development.
Patient‑reported OutcomesA prior clinical study showed efzofitimod produced improvements in a validated patient‑reported lung symptom score that exceeded the threshold considered clinically meaningful, strengthening efficacy claims in discussions with regulators and clinicians.
Bears Say
Investor SentimentAnalyst Neutral ratings reflect a 'show me' view after the Phase 3 study missed its primary endpoint, increasing investor skepticism and constraining upside for the stock.
Regulatory RiskThe FDA may require a new Phase 3 trial if secondary or subgroup data are not accepted at a Type C meeting, creating a significant development delay and increasing the need for additional funding.
Trial Design RiskStrong improvement among placebo patients during steroid tapering reduces the ability to demonstrate a treatment benefit in future trials, complicating trial design and approval prospects.
aTyr Pharma News
ATYR FAQ
What was Atyr Pharma Inc.’s price range in the past 12 months?
Atyr Pharma Inc. lowest stock price was $0.64 and its highest was $7.29 in the past 12 months.
What is Atyr Pharma Inc.’s market cap?
Atyr Pharma Inc.’s market cap is $73.73M.
When is Atyr Pharma Inc.’s upcoming earnings report date?
Atyr Pharma Inc.’s upcoming earnings report date is May 13, 2026 which is in 44 days.
How were Atyr Pharma Inc.’s earnings last quarter?
Atyr Pharma Inc. released its earnings results on Mar 05, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.044.
Is Atyr Pharma Inc. overvalued?
According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued.
Does Atyr Pharma Inc. pay dividends?
Atyr Pharma Inc. does not currently pay dividends.
What is Atyr Pharma Inc.’s EPS estimate?
Atyr Pharma Inc.’s EPS estimate is -0.13.
How many shares outstanding does Atyr Pharma Inc. have?
Atyr Pharma Inc. has 98,051,210 shares outstanding.
What happened to Atyr Pharma Inc.’s price movement after its last earnings report?
Atyr Pharma Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went down -8.647%.
Which hedge fund is a major shareholder of Atyr Pharma Inc.?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.33 (877.33% Upside)
$7.33 (877.33% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 250.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.93%
12-Months-Change
Fundamentals
Return on Equity
-99.62%
Trailing 12-Months
Asset Growth
-3.97%
Trailing 12-Months
Company Description
Atyr Pharma Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Stock 12 Month Forecast
Average Price Target
$7.33
▲(877.33% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.45% Insiders
26.46% Mutual Funds
1.81% Other Institutional Investors
61.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---